Drug Abuse Science Gets Partial Public Peep Show
Published Date: 3/25/2025
Notice
Summary
The National Institute on Drug Abuse is holding a virtual meeting on May 13, 2025, to review grant applications and discuss important drug research topics. This meeting affects researchers and organizations seeking funding, with some parts open to the public and others private to protect sensitive info. No direct money changes are announced, but grant decisions could impact future funding.
Analyzed Economic Effects
5 provisions identified: 4 benefits, 0 costs, 1 mixed.
NIDA Will Review Grant Applications
On May 13, 2025, the National Advisory Council on Drug Abuse will meet virtually to review and evaluate grant applications (closed session 11:00 a.m. to 12:15 p.m.). This meeting directly concerns researchers and organizations that have submitted grant applications to the Institute.
Open Session Videocast for Public Viewing
The Council's open session on May 13, 2025, from 1:30 p.m. to 5:00 p.m. will be videocast and can be accessed from the NIH Videocasting and Podcasting website. Anyone may view the presentations and business of the Council via that videocast.
Portion Closed to Protect Confidential Information
A portion of the May 13, 2025 meeting (11:00 a.m. to 12:15 p.m.) will be closed to the public under 5 U.S.C. 552b(c)(4) and (c)(6) to protect confidential trade secrets, commercial property, patentable material, and personal information tied to grant applications. That closed review applies to applicants whose materials could disclose confidential or personally sensitive information.
Anyone May File Written Comments
Any interested person may file written comments for the committee by emailing Dr. Gillian Acca; comments should include name, address, telephone number, and, when applicable, business or professional affiliation. The notice provides a clear, open channel for public input to the Council.
Accessibility Accommodations Available by Request
Individuals who plan to view the virtual meeting and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify Dr. Gillian Acca by email five days before the May 13, 2025 meeting. The Institute provides a process to request accommodations for the videocast.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-22871, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in early December 2026 to review and evaluate grant applications. These meetings affect researchers and small businesses seeking funding for eye disease, neuronal injury, infectious diseases, and related projects. No public access is allowed to protect private info and trade secrets, but these reviews help decide who gets research money.
2026-22550, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding two closed virtual meetings on November 30, 2026, to review important grant applications. These meetings affect researchers applying for funding in cardiovascular sciences and tobacco regulatory science. No public access is allowed to protect private info and trade secrets, and the reviews help decide who gets research money.
2026-22558, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in early December 2026 to review and evaluate grant applications. These meetings affect researchers and small businesses seeking funding for health-related projects, ensuring privacy for sensitive information. No direct money changes are announced, but these reviews help decide who gets research grants.
2026-22339, Prospective Grant of Exclusive Patent License: Catheter-Based Intramyocardial Ablation for Treating Ventricular Arrhythmia in a Human
The National Institutes of Health plans to give AntaraCore Systems, Inc. an exclusive license to use new catheter technology that treats dangerous heart rhythm problems called ventricular arrhythmia. This means AntaraCore will have special rights to develop and sell this life-saving treatment. If you want to comment or apply for a license, you must do so by December 2, 2026.
2026-22196, National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meeting
The National Institute of Diabetes and Digestive and Kidney Diseases is holding a public meeting on May 12, 2027, to discuss important council business and review grant applications. People interested can attend in person or online, but space is limited and some parts of the meeting will be private to protect sensitive information. This meeting affects researchers and organizations seeking funding and sets the stage for future diabetes and kidney disease research support.
2026-22111, Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Meeting
The Eunice Kennedy Shriver National Institute of Child Health & Human Development is holding a virtual meeting on June 4, 2027, to share updates and review grant applications and staff performance. The first half is open to the public, while the second half is private to protect personal privacy. This meeting affects researchers and staff involved with NICHD grants and projects, with no direct cost changes announced.
Previous / Next Documents
Previous: 2025-04980, National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting
The National Institute of Diabetes and Digestive and Kidney Diseases is holding a private virtual meeting on May 1, 2025, to review grant applications. This meeting affects researchers seeking funding for diabetes, digestive, and kidney disease studies. No public access or money changes are involved, but the review helps decide who gets research support.
Next: 2025-04982, Certain Active Matrix Organic Light-Emitting Diode Display Panels and Modules for Mobile Devices, and Components Thereof; Notice of the Commission's Final Determination Finding No Violation of Section 337; Termination of the Investigation
The U.S. International Trade Commission has decided that certain OLED display panels and parts for mobile devices don’t violate any patent rules. This means the investigation started by Samsung Display is officially over, and no penalties or import bans will happen. Companies making or selling these parts in the U.S. can keep doing business without worry.